SOLVSolventum Corp
Surgical & Medical Instruments & Apparatus
- Revenue
- $8.3B
- 0.9% YoY
- Operating margin
- 26.2%
- 109% YoY
- EBITDA
- $2.7B
- 68% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.8×
- $4.7B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired24% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear40% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|
| Revenue | $8.1B | $8.2B | $8.3B | $8.3B | 0.9% |
| Operating income | $1.7B | $1.7B | $1.0B | $2.2B | 111% |
| Net income | $1.3B | $1.3B | $479M | $1.6B | 225% |
| Operating cash flow | $1.7B | $1.9B | $1.2B | $369M | 69% |
| Capex | $251M | $290M | $380M | $379M | 0.3% |
| Stock-based comp | $37M | $39M | $112M | $161M | 44% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.